Healthcare company Perrigo Company plc (NYSE:PRGO) (TASE:PRGO) disclosed on Wednesday the receipt of the tentative approval from the US Food and Drug Administration for the generic version of Prolensa (bromfenac ophthalmic solution) 0.07% for treating ocular pain in patients.
In conjunction with the US FDA's tentative approval,the company has settled litigation with Bausch & Lomb Inc for Prolensa (bromfenac ophthalmic solution) 0.07%.
According to the company, Prolensa (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
For the last 12 months, the branded market sales of Prolensa Ophthalmic Solution 0.07% were approximately USD113m, concluded the company.
Xbrane Biopharma updates product portfolio
Aurobindo Pharma USA to acquire section of Sandoz US portfolio from Novartis
Novartis to divest parts of Sandoz US portfolio to Aurobindo
Absorption Systems wins Japanese patent for In Vitro Dissolution Absorption System (IDAS2)
Aetna Coverage Decision Extends Abbott's Pain Therapy Option in US
Olon acquires API manufacturing facility in Mahad
Olon acquires API manufacturing facility in Mahad, India
Upsher-Smith unveils generic Lomotil (diphenoxylate hydrochloride and atropine sulfate tablets)
Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the US
Amneal Pharmaceutical signs 10-year license and supply contract with Jerome Stevens Pharmaceuticals
The US FDA approves first generic EpiPen for the emergency treatment of allergic reactions
US FDA Approves Acute Care Cardiovascular Drug Sodium Nitroprusside Injection
Mylan Launches First Generic for Adcirca Tablets
Mylan unveils first generic Adcirca Tablets for treating pulmonary arterial hypertension in the US